推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 近日，臺(tái)灣衛(wèi)生管理部門發(fā)布公告，修訂“應(yīng)施收入中藥材的相關(guān)查驗(yàn)規(guī)定”，自今年1月1日起生效，該措施對輸臺(tái)中藥材質(zhì)量安全提出更高要求。
據(jù)廈門檢驗(yàn)檢疫局有關(guān)人士透露，公告對實(shí)施書面審查的輸臺(tái)中藥材品種由16種增加為30種；現(xiàn)行書面審查的8項(xiàng)中藥材調(diào)整為抽批檢驗(yàn)方式查驗(yàn)；新增紅耆為抽批檢驗(yàn)，新增防風(fēng)等13項(xiàng)中藥材書面審查要求；新增二氧化硫檢查法、食品中殘留農(nóng)藥檢驗(yàn)方法-多重殘留分析方法兩項(xiàng)法定檢驗(yàn)方法；實(shí)行新的檢驗(yàn)項(xiàng)目及標(biāo)準(zhǔn)。
此公告生效后，對列入“應(yīng)施輸入查驗(yàn)中藥材品名明細(xì)表”名單中的中藥材，臺(tái)灣方面將加強(qiáng)抽批檢驗(yàn)和書面審查，對發(fā)現(xiàn)不合格的中藥材實(shí)施退運(yùn)和銷毀處理，不允許通關(guān)。
從2016年1月1日至2016年12月23日，廈門口岸共輸臺(tái)中藥材418噸，占廈門口岸出口中藥材80%，主要品種有黃芪、黨參、當(dāng)歸等100多個(gè)品種，出口作為臺(tái)灣地區(qū)藥廠制藥原料使用。廈門檢驗(yàn)檢疫局提醒我省企業(yè)關(guān)注相關(guān)變化。
